Entity

Time filter

Source Type


Planche V.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Brochet C.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Bakkouch A.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Bernard M.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Bernard M.,University of Paris Descartes
Annales de Biologie Clinique | Year: 2010

The aim of this work is to establish a pre-analytical approach suitable for the neuron-specific enolase (NSE) measurement. This enzyme which is synthesized by neurons and neuroendocrine cells, is a marker useful for the diagnosis and the monitoring of patients with neuroendocrine tumors (neuroblastoma, small cell lung cancer) and during stroke to assess neuronal damage. This NSE measurement is very sensitive to hemolysis due to the abundance of the enzyme in red blood cells. Two methods of evaluation of hemolysis have been compared: the determination of free haemoglobin (Hb) by spectrophotometry and the indirect measurement of an hemolytic index with a multiparameter analyzer, the Modular® (Roche Diagnostics). The correlation between these 2 methods on 42 samples is very satisfactory: Y (free Hb) = 12.337 X (index) + 31.743 r = 0.997. The NSE assay is based on TRACE (Time Resolved Amplified Cryptate Emission) technology, on a Kryptor® (BRAHMS). The influence of hemolysis on the determination of NSE was confirmed by overloading with hemoglobin (hemolysate) 3 pools of serum with NSE concentrations close to the threeshold decision. The determination of NSE shows an increase in concentration parallely to the hemolytic index (about 150% for an hemolytic index of 10). Consequently, in our laboratory the NSE determination is realized only for samples presenting an hemolytic index ≤ 10, this allowing a good monitoring of kinetics of this marker. Source


Brochet C.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Henquet S.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Bernard M.,Services de Biochimie Metabolique et de Biochimie Endocrinienne et Oncologique | Bernard M.,University of Paris Descartes
Immuno-Analyse et Biologie Specialisee | Year: 2012

" A Desintegrin And Metalloprotease 12" (ADAM12) metalloprotease involved into growth and cell-cell interactions, is synthesised by placenta during pregnancy and is implicated in fetal growth. Recently, its overexpression has been described in various human cancers. This multidomain transmembrane enzyme possesses proteolytic function on many substrates (IGFBP and HB-EGF...) suggesting its role in cell growth and hypertrophy. In addition, ADAM12 with its disintegrin-like domain, plays a role in apoptic process, differenciation and organogenesis. Because of the development of automatized techniques, maternal serum ADAM12 has been proposed as supplementary marker in Down'syndrome screening or as potential marker of aneuploidy and pre-eclampsia. The various results due to analytical variability suggest studies on larger series of samples. ADAM12 seems to play an important role in various pathological situations (cancer, musculosketal disorders, cardiac hypertrophy, neurological disorders). At last, inhibition of ADAM12 has been proposed as therapeutic target in cardiology or to treat cancer. © 2012 Elsevier Masson SAS. Source

Discover hidden collaborations